BiotechTube

peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liver Cirrhosis

Conditions

Liver Cirrhosis, Chronic Hepatitis C

Trial Timeline

Jun 1, 2006 → Jun 1, 2010

NCT ID
NCT00304551

About peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin

peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin is a phase 3 stage product being developed by Chugai Pharmaceutical for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00304551. Target conditions include Liver Cirrhosis, Chronic Hepatitis C.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00304551Phase 3Completed

Competing Products

20 competing products in Liver Cirrhosis

See all competitors
ProductCompanyStageHype Score
LanifibranorInventivaPhase 2
47
GODEX + PlaceboCelltrionPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
TacrolimusAstellas PharmaPre-clinical
23
ATG (Fresenius Biotech)Astellas PharmaPhase 2
52
Advagraf + Prograf + PrografAstellas PharmaApproved
85
Prograf + AdvagrafAstellas PharmaApproved
85
ADVAGRAF®Astellas PharmaApproved
85
Prograf + MR4Astellas PharmaPhase 3
77
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimus modified release (MR) + tacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 3
77
Prograf-XL + Prograf + MMFAstellas PharmaPhase 3
77
micafungin + fluconazole + liposomal amphotericin B + caspofunginAstellas PharmaPhase 3
77
Tacrolimus granules + Tacrolimus granulesAstellas PharmaApproved
85
FK506E (modified release tacrolimus) + Prograf (tacrolimus)Astellas PharmaPhase 3
77
FK778Astellas PharmaPhase 2
52
Tacrolimus modified-release + PrografAstellas PharmaPhase 3
77
Advagraf + PrografAstellas PharmaApproved
85
Prograf + FK506MR capsuleAstellas PharmaPhase 3
77

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77